Stronger Together
About MyoGenex
Rewriting the Code. Restoring the Heart.
MyoGenex is a biotechnology company advancing precision RNA medicine for inherited cardiovascular diseases. Our mission is to translate breakthroughs in RNA biology into innovative therapies that address the underlying genetic causes of life-threatening heart conditions.
Our initial focus is desmoplakin-associated arrhythmogenic cardiomyopathy (DSP-ACM), a rare inherited disease that can lead to ventricular arrhythmias, progressive heart failure, and sudden cardiac death. While current treatments help manage symptoms and reduce risk, they do not correct the molecular mechanisms that drive disease progression.
At MyoGenex, we are developing a research platform that integrates complementary RNA-based technologies to address disease at its source. By combining advances in RNA engineering, gene regulation, and precision medicine, we aim to create therapies that restore cellular function rather than simply treating symptoms.
Although our first programs are focused on DSP-ACM, our vision extends much further. We believe the technologies developed at MyoGenex can serve as a foundation for future therapies targeting a broad range of inherited cardiovascular disorders and other genetic diseases.
Our Mission
To develop transformative RNA medicines that address the root causes of inherited diseases and improve the lives of patients and families affected by rare genetic disorders.
Our Vision
To become a global leader in precision RNA medicine by pioneering innovative therapies that redefine how genetic diseases are treated.
Our Scientific Approach
Our research explores multiple RNA-based technologies, including gene modulation, RNA engineering, and precision molecular medicine. Every program is guided by scientific rigor, translational innovation, and a commitment to developing therapies with meaningful clinical potential.
Our Values
Patients First
Every discovery begins with the goal of improving the lives of patients and families.
Scientific Excellence
We pursue rigorous, evidence-driven research with integrity and transparency.
Innovation
We challenge conventional approaches and embrace bold scientific ideas with the potential to transform medicine.
Collaboration
We believe the greatest advances come from partnerships among researchers, clinicians, patient communities, and industry.
Integrity
We are committed to ethical science, responsible innovation, and earning the trust of the communities we serve.
Looking Ahead
MyoGenex is building the scientific foundation for the next generation of precision RNA medicines. As our research advances, we look forward to collaborating with academic institutions, clinicians, patient advocacy organizations, strategic partners, investors, and the broader scientific community to accelerate the development of therapies for patients with rare genetic diseases.
Together, we envision a future where the genetic causes of disease can be addressed with precision, innovation, and hope.
Driven by Science. Inspired by Patients.
MyoGenex was founded with a simple but ambitious vision: to develop innovative precision RNA medicines that address the root causes of inherited genetic diseases.
Our company was born from the intersection of scientific expertise and personal experience. As a family directly affected by a rare inherited heart disease, we understand the urgency of developing therapies that go beyond symptom management to target disease at its source. This perspective shapes every aspect of our mission and commitment to patients.
Although MyoGenex is in its early stages, we are building a collaborative organization grounded in scientific excellence, innovation, integrity, and patient advocacy.
Carolyn Kaya
Founder & Chief Executive Officer
Carolyn Kaya is the Founder of MyoGenex and brings more than 25 years of experience in biotechnology and pharmaceutical research and development.
Throughout her career, Carolyn has contributed to drug discovery, translational research, laboratory operations, assay development, cell biology, molecular biology, biomarker research, and cross-functional scientific leadership across biotechnology, pharmaceutical, and academic organizations. She has worked in both research and operational leadership roles supporting therapeutic development from early discovery through preclinical research.
Carolyn is also a patient living with desmoplakin-associated arrhythmogenic cardiomyopathy (DSP-ACM), a rare inherited genetic heart disease. Following her diagnosis, she became deeply committed to advancing research aimed at addressing the underlying molecular causes of the disease.
This unique combination of scientific expertise and lived experience provides the foundation for MyoGenex’s patient-centered approach to innovation. Carolyn is passionate about translating emerging advances in RNA biology into therapies that have the potential to improve the lives of individuals and families affected by rare genetic diseases.
She is currently completing her Master of Business Administration (MBA) with a concentration in Strategic Operations, complementing her scientific background with expertise in biotechnology commercialization, organizational leadership, and strategic growth.
Dr. Tolga Kaya, MBA
Project Manager
Dr. Tolga Kaya serves as Project Manager for MyoGenex, supporting the company’s strategic planning, operational coordination, and organizational development.
With an MBA and experience managing multidisciplinary initiatives, Dr. Kaya helps guide project execution, business operations, and long-term planning as MyoGenex advances its research and development objectives. He works closely with scientific collaborators and external partners to coordinate activities across the company’s growing programs.
Dr. Kaya shares MyoGenex’s commitment to scientific innovation, operational excellence, and building an organization focused on improving the lives of patients with rare inherited diseases.
Our Vision
We believe patients deserve therapies that address the biological causes of disease—not only the symptoms.
MyoGenex is dedicated to advancing innovative RNA-based approaches that have the potential to transform the treatment of rare inherited diseases. By combining scientific rigor, collaborative partnerships, and a patient-first philosophy, we aspire to build a biotechnology company capable of delivering meaningful advances for families facing conditions with limited treatment options.
For us, this mission is both professional and deeply personal.